Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReJoin for Knee Osteoarthritis
NCT02641860Phase 1Completed
- Sponsor
- AbelZeta
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogenic adipose tissue-derived mesenchymal progenitor cells in knee osteoarthritis (OA) (3 arms), sponsored by AbelZeta. Primary endpoints: Adverse Events and Serious Adverse Events at 48 weeks and Western Ontario and McMaster Universities Osteoarthritis Index at 48 weeks. Started Dec 2015; status: completed.
02
Drugs
allogenic adipose tissue-derived mesenchymal progenitor cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02641860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641860.